Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model

Translational Psychiatry

Volumn 7, Issue 12, 2017, Pages

  Yang, Chun ^a,b   Qu, Youge ^a   Fujita, Yuko ^a   Ren, Qian ^a   Ma, Min ^a   Dong, Chao ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; RNA 16S; ANTIDEPRESSANT AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN; CHEMICAL COMPOSITION; CHRONIC SOCIAL DEFEAT STRESS; CONTROLLED STUDY; DELTAPROTEOBACTERIA; DEPRESSION; DISEASE PREDISPOSITION; ENANTIOMER; FORCED SWIM TEST; GENE SEQUENCE; INTESTINE FLORA; LOCOMOTION; MOUSE; NONHUMAN; PHYLUM; SOCIAL STRESS; SUCROSE PREFERENCE TEST; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; MALE; MENTAL STRESS; MICROBIOLOGY; SOCIAL DOMINANCE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; GASTROINTESTINAL MICROBIOME; KETAMINE; MALE; MICE; MICE, INBRED C57BL; SOCIAL DOMINANCE; STRESS, PSYCHOLOGICAL;

EID: 85034566064     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/s41398-017-0031-4     Document Type: Article

References (66)

1. Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351-354 (2000).
2. Zarate, C. A. Jr et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864 (2006).
3. Murrough, J. W. et al. Antidepressant efficacy of ketamine in treatmentresistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry 170, 1134-1142 (2013).
4. Diazgranados, N. et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67, 793-802 (2010).
5. Zarate, C. A. Jr et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71, 939-946 (2012).
6. Newport, D. J. et al. APA Council of Research Task Force on Novel Biomarkers and Treatments Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am. J. Psychiatry 172, 950-966 (2015).
7. Kishimoto, T. et al. Single-dose infusion ketamine and non-ketamine Nmethyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol. Med. 46, 1459-1472 (2016).
8. Diazgranados, N. et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatmentresistant major depressive disorder. J. Clin. Psychiatry 71, 1605-1611 (2010).
9. Price, R. B. et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress. Anxiety 31, 335-343 (2014).
10. Wilkinson, S. T. & Sanacora, G. Ketamine: a potential rapid-acting antisuicidal agent? Depress. Anxiety 33, 711-717 (2016).
11. Krystal, J. H. et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-241 (1994).
12. Singh, J. B. et al. A double-blind, randomized, placebo-controlled, dosefrequency study of intravenous ketamine in patients with treatment-resistant repression. Am. J. Psychiatry 173, 816-826 (2016).
13. Krystal, J. H., Sanacora, G. & Duman, R. S. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol. Psychiatry 73, 1133-1141 (2013).
14. Monteggia, L. M. & Zarate, C. Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr. Opin. Neurobiol. 30, 139-143 (2015).
15. Duman, R. S., Aghajanian, G. K., Sanacora, G. & Krystal, J. H. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat. Med. 22, 238-249 (2016).
16. Hashimoto, K. R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol. Med. 46, 2449-2451 (2016).
17. Hashimoto, K. Ketamine's antidepressant action: beyond NMDA receptor inhibition. Expert. Opin. Ther. Targets 173, 1389-1392 (2016).
18. Hashimoto, K. (ed.) The NMDA Receptors. Ch. 4, 69-81 (Humana Press: New York, USA, 2017).
19. Newport, D. J., Schatzberg, A. F. & Nemeroff, C. B. Whither ketamine as an antidepressant: panacea or toxin? Depress. Anxiety 33, 685-688 (2016).
20. Yang, C. & Hashimoto, K. Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology 231, 2041-2042 (2014).
21. Hashimoto, K. Detrimental side effects of repeated ketamine infusions in the brain. Am. J. Psychiatry 173, 1044-1045 (2016).
22. Zhu, W. et al. Risks associated with misuse of ketamine as a rapid-acting antidepressant. Neurosci. Bull. 32, 557-564 (2016).
23. Sanacora, G. et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 74, 399-405 (2017).
24. Domino, E. F. Taming the ketamine tiger. 1965. Anesthesiology 113, 678-684 (2010).
25. Zhang, J. C., Li, S. X. & Hashimoto, K. R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S( + )-ketamine. Pharmacol. Biochem. Behav. 116, 137-141 (2014).
26. Yang, C. et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl. Psychiatry 5, e632 (2015).
27. Zanos, P. et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533, 481-486 (2016).
28. Fukumoto, K. et al. Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J. Pharmacol. Exp. Ther. 361, 9-16 (2017).
29. Yang, C. et al. (R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol. Psychiatry 82, e43-e44 (2017).
30. Yang C. et al. Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol. Psychiatry https://doi.org/10.1016/j.biopsych.2017.05.016 (2017).
31. Yang, C., Han, M., Zhang, J. C., Ren, Q. & Hashimoto, K. Loss of parvalbuminimmunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res. 239, 281-283 (2016).
32. Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S. & Tsukada, H. Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur. Arch. Psychiatry Clin. Neurosci. 267, 173-176 (2017).
33. Sommer, F. & Backhed, F. The gut microbiota - masters of host development and physiology. Nat. Rev. Microbiol. 11, 227-238 (2013).
34. Kelly, J. R., Clarke, G., Cryan, J. F. & Dinan, T. G. Brain-gut-microbiota axis: challenges for translation in psychiatry. Ann. Epidemiol. 26, 366-372 (2016).
35. Fung, T., Olson, C. A. & Hsiao, E. Interactions between themicrobiota, immune and nervous systems in health and disease. Nat. Rev. Neurosci. 20, 145-155 (2017).
36. Jiang, H. et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav. Immun. 48, 186-194 (2015).
37. Wong, M. L. et al. Inflammasome signaling affects anxiety-and depressive-like behavior and gut microbiome composition. Mol. Psychiatry 21, 797-805 (2016).
38. Zheng, P. et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Mol. Psychiatry 21, 786-796 (2016).
39. Dinan, T. G. & Cryan, J. F. Mood by microbe: towards clinical translation. Genome Med. 6, 36 (2016).
40. Foster, J. A. Gut microbiome and behavior: focus on neuroimmune interactions. Int. Rev. Neurosci. 131, 49-65 (2016).
41. Yang, C. et al. Bifidobacterium in the gut microbiota confer resilience to chronic social defeat stress in mice. Sci. Rep. 7, 45942 (2017).
42. Zhang, J. C. et al. Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut-microbiotabrain axis. Transl. Psychiatry 7, e1138 (2017).
43. Burokas, A. et al. Targeting the microbiota-gut-brain axis: prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice. Biol. Psychiatry https://doi.org/10.1016/j.biopsych.2016.12.031 (2017).
44. Ho, P. & Ross, D. A. More than a gut feeling: the implications of the gut microbiota in psychiatry. Biol. Psychiatry 81, e35-e37 (2017).
45. Macedo, D. et al. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. J. Affect. Disord. 208, 22-32 (2017).
46. Zhang, J. C. et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology 232, 4325-4335 (2015).
47. Yang, B. et al. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology 233, 3647-3657 (2016).
48. Ren, Q. et al. Gene deciency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc. Natl. Acad. Sci. USA 113, E1944-1952 (2016).
49. Yao, W. et al. Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice. Sci. Rep. 6, 30659 (2016).
50. Ma, M. et al. Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: role of BDNF-TrkB signaling. Sci. Rep. 6, 39209 (2016).
51. Schloss, P. D. et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75, 7537-7541 (2009).
52. Li, W., Fu, L., Niu, B., Wu, S. & Wooley, J. Ultrafast clustering algorithms for metagenomic sequence analysis. Brief. Bioinform. 13, 656-668 (2012).
53. Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 73, 5261-5267 (2007).
54. Roediger, W. E., Moore, J. & Babidge, W. Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig. Dis. Sci. 42, 1571-1579 (1997).
55. Warren, Y. A., Citron, D. M., Merriam, C. V. & Goldstein, E. J. C. Biochemical differentiation and comparison of Desulfovibrio species and other phenotypically similar genera. J. Clin. Microbiol. 43, 4041-4045 (2005).
56. Singh, S. B. & Lin, H. C. Hydrogen sulfate in physiology and diseases of the digestive tract. Microorganisms 3, 866-889 (2015).
57. Sen, N. Functional and molecular insights of hydrogen sulfate signaling and protein sulfhydration. J. Mol. Biol. 429, 543-561 (2017).
58. Zhang, C. et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J. 4, 232-241 (2010).
59. Levine, J., Ellis, C. J., Furne, J. K., Springfield, J. & Levitt, M. D. Fecal hydrogen sulfide production in ulcerative colitis. Am. J. Gastroenterol. 93, 83-87 (1998).
60. Loubinoux, J., Bronowicki, J. P., Pereira, I. A. C., Mougenel, J. L. & Faou, A. E. Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. FEMS Microbiol. Ecol. 40, 107-112 (2002).
61. Jangi, S. et al. Alterations of the human gut microbiome in multiple sclerosis. Nat. Commun. 7, 12015 (2016).
62. De Kock, M., Loix, S. & Lavand'homme, P. Ketamine and peripheral inflammation. CNS Neurosci. 19, 403-410 (2013).
63. Yang, J. J. et al. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol. Psychiatry 77, e19-20 (2015).
64. Kiraly, D. D. et al. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl. Psychiatry 7, e1065 (2017).
65. Xie, Z. M. et al. Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine. Sci. Rep. 7, 3124 (2017).
66. O'Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G. & Cryan, J. F. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav. Brain Res. 277, 32-48 (2015).